Christopher M Knapp
Christopher M Knapp
Sr. Engineer I, Moderna Therapeutics
Verified email at andrew.cmu.edu
TitleCited byYear
Lipidoid Nanoparticles for siRNA Delivery to the Intestinal Epithelium: In Vitro Investigations in a Caco-2 Model
RL Ball, CM Knapp, KA Whitehead
PloS one 10 (7), e0133154, 2015
242015
In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma
CM Knapp, KA Whitehead
Expert opinion on drug delivery 11 (12), 1923-1937, 2014
212014
Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma
CM Knapp, J He, J Lister, KA Whitehead
Experimental Biology and Medicine 241 (9), 1007-1013, 2016
172016
Branched‐Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH
KA Hajj, RL Ball, SB Deluty, SR Singh, D Strelkova, CM Knapp, ...
Small 15 (6), 1805097, 2019
92019
Lipidoid tail structure strongly influences siRNA delivery activity
CM Knapp, P Guo, KA Whitehead
Cellular and Molecular Bioengineering 9 (3), 305-314, 2016
62016
Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma
CM Knapp, J He, J Lister, KA Whitehead
Bioengineering & translational medicine 3 (2), 138-147, 2018
22018
Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model
J He, KA Hajj, CM Knapp, KA Whitehead
Experimental Biology and Medicine, 1535370219857594, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–7